M. Davis and Sons, Inc. has been awarded the National Safety Excellence Award, which is the industry’s leading safety laurel that honors both merit shop general and specialty contractors.
Long Beach, CA, 2018-Mar-30 — /EPR Network/ — Associated Builders and Contractors Delaware Chapter announced the winners of the prestigious Excellence in Construction award during its 28th annual celebration held in Long Beach, California.
The award was received by the construction and fabrication company M. Davis and Sons received amidst resounding applause.
Released on: June 18, 2015, 3:28 am (EDT)
Author: MIKE KERWIEN
Industry: Construction, Small Business
WILMINGTON, DE, June 18, 2015 — /EPR NETWORK/ — M. Davis, the fifth generation woman-owned Industrial Contractor and Fabricator headquartered in Wilmington, DE has named Christina MacMillan its Manager of Supplier Diversity. Christina MacMillan will enhance the program by working with diverse vendors to help identify opportunities with M. Davis. This will enable M. Davis to continue promoting economic growth and community development through our diversity and inclusion initiatives while also expanding our current supplier base to include the best and brightest.
Released on: December 18, 2014, 12:59 pm (EST)
Author: Experimentica Ltd.
Kuopio, Finland, December 18, 2014 — /EPR NETWORK/ — The Lions Eye Institute (LEI) and Experimentica Ltd., a global ophthalmic contract research organization (CRO) announced today that they have entered into an exclusive license agreement for the Akimba mouse model for diabetic retinopathy for contract research. The license agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
Released on: December 01, 2014, 2:30 pm (EST)
Author: ViroCarb Inc.
Industry: Biotech, Healthcare, Pharmaceuticals
Toronto, Canada, December 01, 2014 — /EPR NETWORK/ — ViroCarb Inc. has launched a worldwide crowd funding campaign to promote the development of its new HIV infection inhibitor.
WORLD AIDS DAY – Make a donation to save lives from AIDS! Support new treatment development at: https://www.indiegogo.com/projects/funding-a-new-therapy-against-drug-resistant-hiv/x/9240077
Despite the great progress made in HIV/AIDS treatment, there is still an urgent need for new drugs, particularly for people who have had to abandon existing treatments due to HIV drug resistance and side effects.
Released on: May 28, 2014, 5:11 pm (EDT)
Author: HD Biosciences Co.,Ltd.
Industry: Pharmaceuticals, Biotech
Shanghai, May 28, 2014 — /EPR NETWORK/ — HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology. This joint effort will focus on both international and Chinese markets to provide innovative medicines for unmet healthcare needs. The agreement includes lead candidate selection pre-clinical development, IND filing, clinical trials, and NDA approvals. Both companies will share financial returns from any successes or products launches.